| Drug Name |
Abiraterone |
| Drug ID |
BADD_D00014 |
| Description |
Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011. |
| Indications and Usage |
Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. |
| Marketing Status |
approved |
| ATC Code |
L02BX03 |
| DrugBank ID |
DB05812
|
| KEGG ID |
Not Available
|
| MeSH ID |
C089740
|
| PubChem ID |
132971
|
| TTD Drug ID |
D02STN
|
| NDC Product Code |
42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165 |
| UNII |
G819A456D0
|
| Synonyms |
abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598 |
